ESMO Asia Congress 2022 | MIMS Malaysia

Is first-line lazertinib monotherapy a potential new SoC for EGFRm NSCLC?

Roshini Claire Anthony, 20230210180001

Patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) exhibited significantly improved progression-free survival (PFS) when treated with lazertinib compared with gefitinib in the first-line setting, results of the LASER301 trial showed.

TACE + apatinib: A potential new strategy for intermediate/advanced HCC?

Roshini Claire Anthony, 20221228180001

In patients with intermediate or advanced hepatocellular carcinoma (HCC), combining transarterial chemoembolization (TACE) with apatinib led to improvement in progression-free survival (PFS), according to a recent study from China.

Relugolix effective, well tolerated in Asian men with advanced prostate cancer

Audrey Abella, 20221223100000

In the subgroup analysis of the HERO trial, the first-in-class oral, highly selective, GnRH* antagonist relugolix was effective and well tolerated in Asian men with advanced prostate cancer.

JAVELIN Bladder 100: Sustained survival benefit with avelumab + BSC in Asians with advanced UC

Elaine Soliven, 20221222000000

Longer-term follow-up results of the JAVELIN Bladder 100 trial continue to show prolonged overall survival (OS) and progression-free survival (PFS) with avelumab first-line maintenance and best supportive care (BSC) among Asian patients with advanced urothelial carcinoma (UC) compared with BSC alone.

More evidence supports osimertinib for EGFR-mutated NSCLC

Elvira Manzano, 20221221000000

Safety data from the phase III ADAURA study support osimertinib as an effective adjuvant therapy for resectable, stage IB–IIIA EGFR-mutated non–small-cell lung cancer (NSCLC), says an expert.

Maintenance olaparib confers survival benefit for HRD+ ovarian cancer patients

Audrey Abella, 20221219100000

In the final overall survival (OS) analysis of the phase III PAOLA-1*/ENGOT-ov25 trial, the addition of olaparib to bevacizumab provided a survival benefit for women with newly diagnosed advanced ovarian cancer with HRD**-positive (HRD+) tumours.

Prostate cancer genomic study shows disparity between Chinese and Caucasians with castration-sensitive disease

Christina Lau, 20221213090934

A large genomic study involving 1,016 Chinese patients with prostate cancer has revealed important differences in castration-sensitive disease between Chinese and Caucasian patients, but the mutation profile of metastatic castration-resistant prostate cancer (mCRPC) is similar between the populations.

Dr James Yang at ESMO Asia Congress 2022

Asians with MET exon 14 skipping NSCLC achieve durable response with tepotinib

Jairia Dela Cruz, 20221212140000

The MET inhibitor tepotinib demonstrates clinically meaningful antitumour activity, with durable efficacy and manageable safety profile in Asian nonsmall cell lung cancer (NSCLC) patients with MET mutations associated with exon 14 skipping, as shown in the subset analysis of the single-arm, phase II VISION study.

Durvalumab plus gemcitabine-cisplatin improves survival in advanced BTC

Stephen Padilla, 20221212120000

First-line treatment with durvalumab plus gemcitabine and cisplatin (GC) leads to improved overall (OS) and progression-free survival (PFS) in advanced biliary tract cancer (BTC) across genomic variants, according to the results of the phase III study TOPAZ-1, presented at the ESMO Asia 2022.

Amivantamab/lazertinib combo shows promise in EGFR-mutated NSCLC

Tristan Manalac, 20221210090000

Among nonsmall cell lung cancer (NSCLC) patients with mutations spanning exons 18 to 21, combination treatment with amivantamab and lazertinib induces high rates of response, reports a study presented at the recent 2022 European Society for Medical Oncology Asia Congress (ESMO Asia 2022).